The published study assessed the effect of pre-treatment with VP025 on 6-OHDA-induced rotational behaviour in response to amphetamine. Treatment with VP025 prior to 6-OHDA administration led to behavioural improvement demonstrated by a substantial (50-75%) and significant (p<0.001) reduction in rotation rate. VP025 also protected against the loss of dopaminergic neurons and provided significant protection against the reduction in levels of striatal dopamine induced by OHDA. The absence of rotations was maintained for up to three weeks while partial protection against the loss of dopaminergic neurons and reduction in striatal dopamine levels was still evident four weeks after lesion induction, indicating that VP025 has a potential long-term neuroprotective effect in this model.
Parkinson's disease, a chronic and progressive neurological condition, affects up to 1.5 million Americans.
While its cause is unknown, the symptoms of Parkinson's disease are primarily the result of degeneration of areas of the brain that control and modulate movement. Symptoms include a number of movement abnormalities such as tremors, slowness of movement, stiffness and rigidity of limbs, and gait or balance problems. As the disease progresses, these symptoms usually increase and impact a person's ability to work and function.
VP025, the lead product candidate from a new class of structurally
related drugs, is being developed for the treatment of chronic
neuro-inflammatory disorders. VP025 is designed to interact with immune
cells leading to the modulation of cytokines - potent chemical messengers
that regulate and control inflammation. Neurological conditions that are
associated with an inflammatory response in the central nervous system
include Alzheimer's disease, Parkinson's disease, multiple sclerosis, and
amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
These indications are characterized by increased levels of inf
|SOURCE Vasogen Inc.|
Copyright©2008 PR Newswire.
All rights reserved